Eli Lilly Expands Pipeline with Strategic Acquisitions

Eli Lilly has significantly diversified its drug development pipeline through a series of recent acquisitions, totaling over $25 billion this year. A notable deal includes Kelonia Therapeutics, aimed at strengthening Lilly's position in oncology cell therapy. These moves are expected to broaden the pharmaceutical giant's focus beyond metabolic medicine.